When is the best time to start HAART; before the CD4 count falls to lower than 350 cells/microL? JAIDS: Journal of Acquired Immune Deficiency Syndromes
There is continuing interest in the longer term effects of highly active antiretroviral therapy (HAART) on the risk of cardiopulmonary events. JAIDS: Journal of Acquired Immune Deficiency Syndromes
The number of HIV-positive patients treated in a hospital and the number of HIV-positive patients treated by the attending physician are examined. What is the probability of dying in the hospital? JAIDS: Journal of Acquired Immune Deficiency Syndromes
In this article 15 factors are identified in the sexually transmitted infection (STI) literature to explain the presence of racial/ethnic disparities in STIs. JAIDS: Journal of Acquired Immune Deficiency Syndromes
Many developing countries that are combating AIDS are facing dire shortages of qualified doctors and nurses as healthcare workers leave for developed countries where they are paid many times more. Reuters Health Information
New research indicates that HIV-infected injection drug users glean as much benefit from highly active antiretroviral therapy (HAART) as do patients without this history. Reuters Health Information
Abbott Laboratories has agreed to pay between $10 million and $27.5 million to settle a lawsuit contending it improperly raised the price of its HIV drug Norvir by 400 percent. Reuters Health Information
Potent synergistic anti-HIV effects can be obtained by using combinations of the CCR5 inhibitor aplaviroc with other anti-HIV drugs. Reuters Health Information
